Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22852656 | 1.00 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL17964132 | 1.00 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL17993054 | 1.00 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL19680677 | 1.00 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL17963999 | 0.93 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL19680726 | 0.93 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL17964014 | 0.93 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL19680667 | 0.93 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL17993289 | 0.93 | LGALS3 (1.00) | LGALS3 | |
| SCHEMBL17993177 | 0.92 | LGALS3 (1.00) | LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026778-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | TIUMBIO CO., LTD. (KR) | 2025-01-23 | — | — | US | disclosed |
| EP-4365181-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | TiumBio Co., Ltd. (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026778-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.